Sun Pharmaceutical Industries has reached a licence agreement with Philogen for the commercialisation of Philogen’s Nidlegy (Daromun) in Australia, New Zealand and Europe.

Nidlegy is a new anti-cancer biopharmaceutical being developed to treat patients with melanoma and non-melanoma skin cancers. It is currently undergoing Phase III clinical studies.

Nidlegy is composed of L19TNF and L19IL2, two active ingredients which are produced separately and then combined before being administered via the intralesional method.

Philogen CEO and CSO Professor Dr Dario Neri stated: “This collaboration will focus on the commercialisation of Nidlegy, a new immunotherapy that brings promise to improve the therapeutic options for patients suffering from melanoma and non-melanoma skin cancers, high-risk conditions with unmet medical need.”

Sun Pharma has been granted exclusive commercialisation rights for Nidlegy in the three countries for the treatment of skin cancers.

Philogen will hold intellectual property rights for Nidlegy in other territories and indications, excluding skin cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It intends to conclude pivotal clinical studies for Nidlegy in Europe and to seek marketing authorisation from the regulatory authorities.

The company will also be involved in the manufacture of commercial supplies.

Sun Pharma will take responsibility for the commercialisation of the product.

Post-commercialisation costs will be split equally between the two companies.

Sun Pharma Western Europe and ANZ business head Hellen De Kloet stated: “This collaboration is in line with our goal to bring innovative products to patients.

“With the expected addition of Nidlegy to our existing Odomzo franchise, we will be well-positioned to provide patient solutions across a broad spectrum of skin cancers in various disease stages.”